CClinicalTrials.gg
Status unknownNCT03455205Updated Mar 6, 2018

Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract .

An interventional study of shenqifuzheng and 0.9%sodium chloride in Digestive Tract, sponsored by Livzon Pharmaceutical Group Inc.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-06.

Sponsored by Livzon Pharmaceutical Group Inc. · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The efficacy and safety of cancer patients in patients with gastrointestinal cancer (chemotherapy) in patients with gastrointestinal tumor (chemotherapy) were prospectively, randomized blind, multicenter clinical trials. They were randomly divided into 2 groups, test group Shenqifuzheng injection of 500 ml, the control group 0.9% sodium chloride injection, 500 ml, intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment. The main curative effect of the clinic was to evaluate the pretreatment of cancer due to the fatigue score of the patients before and after treatment -- the Piper fatigue revision scale was used to evaluate the Chinese version. Assess effectiveness and safety based on clinical assessment

Read the detailed description

Factors for the purpose of this study by observing theShenqifuzheng injection before and after treatment in patients with carcinoma due to fatigue scale scores, the classification of syndromes, the quality of life score changes and related laboratory index, evaluation factors ginseng and astragalus injection on the digestive tract tumor (chemotherapy) in patients with cancer-related fatigue and quality of life improved efficacy and safety. The experimental group was randomly divided into 2 groups, experimental group Shenqifuzheng injection of 500 ml. The control group was 0.9% sodium chloride injection, 500ml, intravenous drip, 1 time daily, 7 days for continuous use, 14 days of rest, and 1 treatment for each 21 days, and 2 courses were observed. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment.

Main efficacy evaluation indexes before and after treatment for cancer-related fatigue rating - adopting the Piper fatigue scale revised Chinese version, compare the experimental group and the control group before and after treatment cancer-related fatigue rating difference have differences. Secondary efficacy evaluation index to compare the ECOG score difference before and after the treatment, the quality of life score difference before and after the treatment, TCM syndrome curative effect, single symptom curative effect of immune function, tumors had curative effect (if any) and chemotherapy completion. Safety assessment includes the observation of vital signs, blood routine, urinary routine, routine stool, liver function, renal function, electrocardiogram examination, and adverse reactions during the treatment.

02

Conditions studied

  • Digestive Tract

Browse trials for

03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

    1. Patients with gastric cancer, esophageal cancer or colorectal cancer diagnosed by pathology or cytology;
  • 2.Diagnostic criteria for cancer-related fatigue;
    1. Syndrome differentiation of Chinese medicine is a syndrome of lung temper;
    1. Estimated survival over 3 months;
    1. ECOG score is less than or equal to 2;
    1. Age 18 \~ 75 years old;
    1. Non-surgical indications or reluctance to operate the surgical treatment;
    1. Have chemotherapeutic indications;
    1. Stop and chemotherapy for more than 1 month;
    1. The patient is willing to accept the treatment of the programme, and can follow the doctor's advice to take the medicine and comply with the patient.

Exclusion criteria

Exclusion Criteria:

    1. The chemotherapy regimen received by the subject was not within the prescribed programme;
    1. Any situation that may hinder the subject from completing the clinical trial, including but not limited to serious, uncontrollable organic lesions or infection:

      1. clinically significant cardiovascular diseases, such as heart failure (NYHA III-IV), uncontrolled coronary heart disease, cardiomyopathy, arrhythmia, etc.
      2. uncontrolled hypertension (systolic pressure is greater than 160 mmHg or diastolic pressure is greater than 100 mmHg, despite the best drug treatment);
      3. serious clinical infection of activity (greater than 3 degrees NCI-CTCAE 4.03)
      4. severe liver and kidney function abnormality (blood creatinine is greater than 1.5 times ULN; ALT or AST is greater than 2.5 times ULN; Bilirubin is greater than 1.5 times ULN.
    1. Patients with symptoms, uncontrollable nerves, mental illness or mental disorders;
    1. Compliance.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    shenqifuzheng injection

    Shenqifuzheng injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens: Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio All test drugs should be covered with dark bags before infusion, and use a dark infusion to guarantee the implementation of the blind method.

    Drug: shenqifuzheng

  • Placebo comparator
    0.9% sodium chloride injection

    0.9% sodium chloride injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens: Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio No interventions have been included in Arm Description for '0.9% sodium chloride injection'

    Drug: 0.9%sodium chloride

Interventions

  • Drugshenqifuzheng

    500ml shenqifuzheng daily(at day 1-7and day22-28)through intravenous infusion.

  • Drug0.9%sodium chloride

    500ml sodium chloride(0.9%)daily(at day 1-7 and day22-28)through intravenous infusion.

05

What researchers measure

Primary outcomes

  1. Piper Fatigue Scale(PFS)

    the score of Piper Fatigue Scale before and after the treatment

    Time frame: 42 days

06

Study locations

1 of 1 sites recruiting
  • First affiliated hospital of guangzhou university of traditional Chinese medicine
    Guangzhou, Guangdong, China
    Recruiting
07

Registry details

Key details

Study ID
NCT03455205
Lead sponsor
Livzon Pharmaceutical Group Inc.
Collaborators
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Responsible party
Sponsor
First posted
Mar 6, 2018
Start date
Dec 24, 2017
Primary completion
Dec 30, 2019 (estimated)
Completion
Dec 30, 2019 (estimated)
Last update
Mar 6, 2018

Study contacts

lin lizhu, Dr.
Contact
13501505588@139.com
13501505588
lin lizhu, Dr.
principal investigator · First affiliated hospital of guangzhou university of traditional Chinese medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion